Pulmonx (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 14,334 Shares of Stock

Key Points

• Pulmonx General Counsel David Lehman sold 14,334 shares at an average price of $2.26, generating approximately $32,395. The sale covered tax-withholding obligations, leaving him with 361,827 shares.
• Pulmonx shares fell 0.9% to $2.26, while the company reported quarterly revenue of $22.76 million and an adjusted loss of $0.24 per share, beating analyst expectations.
• Institutional investors own approximately 91.04% of Pulmonx, and analysts maintain a “Moderate Buy” consensus rating with an average price target of $7.67.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) General Counsel David Lehman sold 14,334 shares of Pulmonx stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,394.84. Following the completion of the transaction, the general counsel directly owned 361,827 shares in the company, valued at approximately $817,729.02. The trade was a 3.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Down 0.9%

Shares of Pulmonx stock traded down $0.02 on Thursday, hitting $2.26. The company had a trading volume of 284,129 shares, compared to its average volume of 512,534. The stock has a 50-day moving average of $1.79 and a 200-day moving average of $1.56. The company has a debt-to-equity ratio of 0.95, a current ratio of 4.32 and a quick ratio of 3.52. Pulmonx Corporation has a twelve month low of $1.13 and a twelve month high of $2.89. The firm has a market capitalization of $97.07 million, a P/E ratio of -1.95 and a beta of 0.34.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%.The firm had revenue of $22.76 million during the quarter, compared to analysts' expectations of $22.39 million. Research analysts predict that Pulmonx Corporation will post -1.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Pulmonx during the 1st quarter worth about $26,000. Cerity Partners LLC bought a new stake in Pulmonx in the fourth quarter valued at approximately $27,000. Opal Capital LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $29,000. Jain Global LLC bought a new position in shares of Pulmonx during the 3rd quarter worth approximately $30,000. Finally, Sei Investments Co. acquired a new position in shares of Pulmonx during the 1st quarter worth approximately $31,000. Institutional investors own 91.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LUNG shares. Wall Street Zen raised Pulmonx from a "sell" rating to a "hold" rating in a research report on Saturday, June 27th. Weiss Ratings upgraded shares of Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pulmonx currently has an average rating of "Moderate Buy" and a consensus price target of $7.67.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source